Compare AVAH & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVAH | LTGO |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2026 |
| Metric | AVAH | LTGO |
|---|---|---|
| Price | $12.84 | $19.95 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 226.7K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1850.00 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $2,433,199,000.00 | N/A |
| Revenue This Year | $7.31 | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $35.73 | ★ N/A |
| Revenue Growth | ★ 20.19 | N/A |
| 52 Week Low | $5.93 | $17.22 |
| 52 Week High | $14.71 | $25.93 |
| Indicator | AVAH | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.32 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $25.17 |
| Average True Range (ATR) | 0.00 | 1.68 |
| MACD | 0.00 | -0.38 |
| Stochastic Oscillator | 0.00 | 15.87 |
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.